Format

Send to

Choose Destination
Arch Toxicol. 2012 Jan;86(1):1-12. doi: 10.1007/s00204-011-0729-7. Epub 2011 Jun 30.

The safety profile of imatinib in CML and GIST: long-term considerations.

Author information

1
Royal Marsden NHS Foundation Trust, London, UK. eirinithanopoulou@gmail.com

Abstract

Imatinib mesylate is considered the standard first-line systemic treatment for patients with chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST) by targeting BCR-ABL and c-KIT tyrosine kinases, respectively. Indeed, imatinib has substantially changed the clinical management and improved the prognosis of both diseases. Treatment with imatinib is generally well tolerated, and the risk for severe adverse effects is low, generally occurring during the early phase of treatment and correlating with imatinib dose, phase of disease and patient's characteristics. This article summarises recent data on safety profile of imatinib for the treatment of CML and GIST, including long-term side effects. Prolonged treatment with imatinib in both diseases demonstrates excellent tolerability. There are few significant concerns and those that have emerged, like cardiotoxicity, have far turned out to be exaggerated.

PMID:
21717109
DOI:
10.1007/s00204-011-0729-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center